RxDoctor Payments Data

Brian Davault, MD

Family Medicine · Wabash, INNPI 1467946368

Payments from drug & device makers

$334in general payments, 2019–2025

Across 19 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$53
  • Novo Nordisk$37
  • Dexcom, Inc.$32
  • GSK$32
  • Inspire Medical Systems, Inc.$29
  • Exact Sciences$24
  • plus $128 from 8 others

What the payments were for

  • Food & beverage$29689%
  • Education$3811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$334 in reported general payments places this provider in the 40th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$4,240
Medicare patients
51
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$110,375
JardianceEmpagliflozin101$110,373
OzempicSemaglutide80$100,300
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$63,311
TrulicityDulaglutide18$35,179
JanuviaSitagliptin Phosphate30$33,284
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$19,653
RybelsusSemaglutide18$19,133
XareltoRivaroxaban26$18,264
MyrbetriqMirabegron19$18,182
Breo ElliptaFluticasone/Vilanterol32$17,947
Fluticasone-SalmeterolFluticasone Propion/Salmeterol99$9,694
Levemir FlexpenInsulin Detemir16$7,318
Fluticasone-VilanterolFluticasone/Vilanterol19$6,790
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$37$119,43398 claims
PfizerEliquis$13$110,37594 claims
Boehringer IngelheimJardiance$53$110,373101 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$32$87,690114 claims
Lilly USA, LLCTrulicity, Humalog$17$37,79429 claims
Astellas Pharma US IncMyrbetriq$21$18,18219 claims
AbbVieSynthroid$16$1,93742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Wabash

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →